Saturday, 23 January 2016

Can You Trust The Cancer Industry?

New Cancer Drug Illustrates Ineffectiveness of Mainstream Cancer Treatment

Mainstream medicine and drug maker Bristol-Myers Squibb (BMS) are touting BMS’s new cancer drug Opdivo (nivolumab) as a “breakthrough” that offers the hope of longer life. A closer look reveals just how cruel and deceptive such claims are and how the new drug, rather than being a new breakthrough, is just one more example of mainstream medicine’s false promises and an indictment of the mainstream medicine’s failure in treating cancer.
One prominently featured TV ad utilizes an attractive view of Chicago as a backdrop and smiling healthy looking actors portraying lung cancer patients. The ad boldly proclaims that Opdivo is a huge breakthrough which works with the patient’s own immune system to “at last offer the hope for longer life” for chemotherapy patients.
Another overblown advertisement for Opdivo proclaims:
Researchers have made what looks like a “once in a generation” breakthrough in fighting cancer, advancing a technique that could become one of the “pillars of oncology,” next to surgery and chemotherapy. The technique enables the immune system, which ordinarily treats malignant cancer cells as if they were healthy, normal cells, to identify and attack tumors.Sounds great, doesn’t it? But what are the “fine print” and audio disclaimers that are slipped in while our attention is diverted by the backdrop and actors? Well, first of all there are the warnings that Opdivo can cause the immune system to attack healthy organs with possible fatal results. Not so great, huh? Among the immune disorders caused by the new drug are Crohn’s Disease, Ulcerative Colitis and Lupus. And then there is the real clincher: In clinical trials of patients with lung cancer, patients who took Opdiva survived for an average of 9.2 months compared to 6 months for those took chemotherapy alone.
Are you kidding me? Only three additional months of life for a cost of up to $100,000? And it is worth nothing that the quality of life during those extra months can be horrific – in one trial which used the new drug in combination with another BMS immune boosting drug (ipilimumab), 30 percent of the patients in the trial dropped out because the side effects became more than they could tolerate. Read more... The truth About Cancer, with Ty Bollinger.